Abstract
To compare user satisfaction and adverse events (AEs) with use of the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol/3 mg drospirenone combined oral contraceptive (COC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have